SEC Form 4 · accession 0001562180-17-004028
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Jonas
Officer — President & CEO · Director
Period of report
Dec 26, 2017
Accepted (ET)
Dec 26, 2017 · 4:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 26, 2017 | M | 50,000 | $0.45 | A | 51,226 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.45 | Dec 26, 2017 | M | 50,000 | D | — | Aug 12, 2023 | Common Stock | 50,000 | 232,552 | D |
Explanation of responses
- F1The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option fully vested on August 12, 2017, subject to continued service through such date.